Brind.

Collaboration agreement for Evkeeza and distribution rights obtained by ORBIT and Regeneron in Turkey and the European Economic Area.

1 report, 1 independent Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Collaboration agreement for Evkeeza and distribution rights obtained by ORBIT and Regeneron in Turkey and the European Economic Area.

Who's involved

What this event is mainly about
ORBITRegeneron Pharmaceuticals

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • ZacksUltragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y Ultragenyx Pharmaceutical RARE reported second-quarter 2025 loss of $1.17 per share, narrower than the Zacks Consensus Estimate of a los